Organon (OGN) P/E (2021 - 2026)
Organon (OGN) P/E from May 14, 2021 to Jun 3, 2026. The TTM Organon (OGN) P/E is 14.23. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Organon (OGN)
| Year | P/E | Change |
|---|---|---|
| 2026 | 14.23 | +43.50% |
| 2025 | 9.92 | +123.33% |
| 2024 | 4.44 | -29.35% |
| 2023 | 6.29 | -10.41% |
| 2022 | 7.02 | +22.77% |
| 2021 | 5.71 | N/A |
Comparison Organon (OGN) P/E with competitors
Organon (OGN) P/E is 14.23.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| NVO | Novo Nordisk | 10.39 | -27.00% |
| GRFS | Grifols SA | 11.29 | -20.69% |
| GSK | GSK Plc | 12.14 | -14.72% |
| PFE | Pfizer Inc | 12.31 | -13.53% |
| SNY | Sanofi | 12.33 | -13.34% |
| BMY | Bristol-Myers Squibb Company | 13.54 | -4.83% |
| BIIB | Biogen Inc | 17.38 | +22.14% |
| GILD | Gilead Sciences Inc | 18.01 | +26.57% |
| JNJ | Johnson & Johnson | 20.68 | +45.33% |
| NVS | Novartis AG | 21.64 | +52.08% |
| AMGN | AMGEN Inc | 23.21 | +63.11% |
| MRK | Merck & Co Inc | 27.45 | +92.88% |
| AZN | Astrazeneca plc | 27.89 | +96.00% |
| LLY | Lilly(Eli) & Company | 45.43 | +219.21% |
| ABBV | Abbvie Inc | 122.69 | +762.10% |